Presenting author
Eric Konofal
3 presentations
W53. A novel disease-modifying strategy for narcolepsy type 1 – preclinical rationale and development roadmap for the Doxa platform
T12. Mazindol IR/SR: A 50-year legacy repositioned as a first-in-class orexin–monoamine modulator for ADHD and arousal-related disorders
T13. Comprehensive multitarget strategy for type 1 diabetes and associated neurological/sleep disorders (DANS): Integrating stem-cell-derived islet replacement, immune modulation, and neuro-circadian therapeutics